Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. By Damian Garde Aug. 24, 2017 Reprints What’s included? Pharmalittle: India’s hard-line pharma rules hit a roadblock; Amgen goes on defense What is it? Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Log In | Learn More Alex Hogan/STAT Good morning, one and all. Damian Garde here, filling in for Ed Silverman on the back half of another week laden with meetings, deadlines, and all the other sundry perils of working life. The plodding end of summer is winding to a close, taking with it the sluggish news cycles, muggy forecasts, and vacation auto-responses, and hopefully giving way to a tranquil autumn. Here’s your morning serving of headlines from the pharma world, wishing you a speedy path to the weekend. And if you hear anything interesting in the meantime, do drop us a line.India’s plans for a crackdown on drug prices and pharmaceutical marketing have run into a legal roadblock, Reuters tells us. The nation’s Department of Pharmaceuticals had proposed a sweeping initiative that would cap prices for certain products, regulate how industry interacts with physicians, and ban brand names for some drugs. But India’s law ministry has now rejected the proposal outright, saying it cannot be implemented under current law and forcing reformers back to the drawing board after a two-year deliberation. Tags legalpharmaceuticalspharmalittleSTAT+ Damian Garde GET STARTED About the Author Reprints [email protected] Pharmalot @damiangarde National Biotech Reporter Damian covers biotech, is a co-writer of The Readout newsletter, and a co-host of “The Readout LOUD” podcast. STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.